logo

For the Inventor, By the Inventor

Osaka, Japan

Kentaro Tanaka

This inventor holds 10 USPTO granted patents and 3 published patent applications. Top assignee: Shionogi Company Limited. Active years: 1981-1988.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kentaro Tanaka. Retrieved from https://idiyas.com/inventor/kentaro-tanaka-u25jbz36

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 

% Patents Active = 100.0

Average Co-Inventor Count = 4.1

ph-index = 3

Forward Citations = 29(Granted Patents)


Location History:

  • Suita, JP (1981 - 1983)
  • Osaka, JP (1984 - 1988)

Company Filing History:

goldMedal10 out of 1,001 
 
Shionogi Company Limited
 patents

Years Active: 1981-1988

Loading Chart...
10 patents (USPTO):Explore Patents
1. 4780530 - Novel interferon alphas (1988-10-25),
2. 4713241 - Bacterial insecticide and production thereof (1987-12-15),
3. 4647408 - Carbapenem-type antibiotics (1987-03-03),
4. 4556517 - Carbapenem derivatives (1985-12-03),
5. 4456686 - Antibiotic PA-39504-X.sub.1 and production thereof (1984-06-26),
6. 4448723 - Antibiotics PA-41746-B and C (1984-05-15),
7. 4387052 - Antibiotic PA-39504-X.sub.3 and production thereof (1983-06-07),
8. 4371617 - Process for preparing thienamycin (1983-02-01),
9. 4362665 - Antibiotic PA-39504-X.sub.1 and production thereof (1982-12-07),
10. 4292241 - Antibiotic PA-31088-IV and production thereof (1981-09-29),

Title: Innovations by Kentaro Tanaka: Pioneering Advances in Biotechnology

Introduction

Kentaro Tanaka, a distinguished inventor located in Osaka, Japan, holds an impressive portfolio of 10 patents. His work is particularly notable in the field of biotechnology, where he has made significant contributions to both human and animal health through his inventions.

Latest Patents

Two of Tanaka's latest patents showcase his innovative research:

1. **Novel Interferon Alphas - Novel IFN.alpha.S51B10 and IFN.alpha.S17H9**: This invention involves the preparation of novel interferons derived from BALL-1 cells induced by Sendai virus, utilizing the well-known recombinant DNA technique. The patent details a DNA sequence encoding interferon .alpha.S51B10 or .alpha.S17H9, a recombinant plasmid for expression in host microorganisms, and a microorganism transformed with this plasmid. Both interferon types exhibit antiviral and anti-tumor properties, making them vital candidates for therapeutic applications in humans and animals.

2. **Bacterial Insecticide and Production Thereof**: This patent focuses on a bacterial insecticide containing an insecticidal substance produced by a practically reversionless asporogenous mutant of Bacillus thuringiensis, specifically Bacillus thuringiensis serovar. kurstaki 290-1. The invention not only details the insecticidal properties of this strain but also covers the production process, contributing to the development of effective biopesticides.

Career Highlights

Kentaro Tanaka is currently affiliated with Shionogi & Company Limited, where he continues to research and develop groundbreaking biotechnological solutions. His expertise has resulted in patents that have the potential to transform medical treatments and agricultural practices.

Collaborations

Throughout his career, Tanaka has collaborated with fellow researchers and coworkers, including Naoki Tsuji and Kouichi Matsumoto. These partnerships have enriched his work, allowing for the exchange of ideas and fostering innovation in their respective fields.

Conclusion

Kentaro Tanaka's contributions to biotechnology are exemplified by his innovative patents that address crucial health and agricultural challenges. His continued research at Shionogi & Company Limited underscores his commitment to advancing technology for the betterment of society.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…